aap Implantate AG is granted SDA-approval for the Chinese market

aap Implantate AG, a biomedical company listed on the Neuer Markt of the Frankfurt Stock Exchange, has received the SDA-approval by China's State Drug Administration to sell its products in the Chinese market. With immediate effect, aap Implantate AG's entire product range can be sold in the People's Republic of China.

Exclusive partner in China is Beijing-based P&T Technologies, which is represented in all industrial and commercial centres in the People's Republic of China either by branches of its own or by local sales partners. In the past months, all necessary marketing and training measures had been undertaken by both sides to ensure that sales could get under way as soon as the approval was granted. So the first shipments are already scheduled for the current quarter.

As Asia's largest threshold country, China is undergoing a dynamic economic development. The simultaneous emergence of an affluent middle class has led to a swift and intensive modernization of the Chinese health system.

In opening up the Chinese market, aap Implantate AG has put in place the second pillar of its strategy for the Asian markets. The company is already conducting successful business in Japan and nearly all other important Asian markets.